Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
NCT07054346 · View on ClinicalTrials.gov ↗
Study Summary
There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of actinium-225 and lutetium-177 radioligand therapies (RLT) in participants with high or very high risk localized or locoregional prostate cancer planning on undergoing a prostatectomy.
Conditions Studied
Interventions
- DRUG 177 Lutetium Prostate-Specific Membrane Antigen 617
- DRUG Actinium-225 Prostate-Specific Membrane Antigen 617
- PROCEDURE Non-investigational, Prostatectomy
- PROCEDURE Prostate Tissue Collection
- PROCEDURE Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)
Study Locations (1)
California
- University of California, San Francisco — San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-07-08 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07054346
The ClinicalTrials.gov registry entry for NCT07054346 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Hope, which has 7 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions — of which 177 Lutetium Prostate-Specific Membrane Antigen 617 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07054346 reports 1 study location spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07054346 about?
NCT07054346 is a clinical study titled "Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617". There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of act...
What is the current status of trial NCT07054346?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2025-07-08. Estimated completion is 2028-04-30.
What conditions does trial NCT07054346 study?
This clinical trial studies the following conditions: Prostate Cancer, Localized Prostate Carcinoma, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Very High Risk Prostate Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07054346?
The interventions under investigation include: 177 Lutetium Prostate-Specific Membrane Antigen 617 (DRUG), Actinium-225 Prostate-Specific Membrane Antigen 617 (DRUG), Non-investigational, Prostatectomy (PROCEDURE), Prostate Tissue Collection (PROCEDURE), Single-photon emission computed tomography (SPECT)/Computerized tomography (CT) (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07054346?
This trial is sponsored by Thomas Hope, which has 7 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07054346 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.